PL362437A1 - Diagnostyka i leczenie jaskry - Google Patents

Diagnostyka i leczenie jaskry

Info

Publication number
PL362437A1
PL362437A1 PL01362437A PL36243701A PL362437A1 PL 362437 A1 PL362437 A1 PL 362437A1 PL 01362437 A PL01362437 A PL 01362437A PL 36243701 A PL36243701 A PL 36243701A PL 362437 A1 PL362437 A1 PL 362437A1
Authority
PL
Poland
Prior art keywords
glaucoma
therapeutics
frp
diagnosing
diagnostics
Prior art date
Application number
PL01362437A
Other languages
English (en)
Other versions
PL208368B1 (pl
Inventor
Abbot F. Clark
John Fingert
Lorette Mcnatt
Edwin M. Stone
Wan-Heng Wang
Original Assignee
Alcon Laboratories, Inc.
University Of Iowa Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Laboratories, Inc., University Of Iowa Research Foundation filed Critical Alcon Laboratories, Inc.
Publication of PL362437A1 publication Critical patent/PL362437A1/pl
Publication of PL208368B1 publication Critical patent/PL208368B1/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G01N2800/168—Glaucoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
PL362437A 2000-02-29 2001-02-26 Sposób diagnozowania jaskry PL208368B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18607300P 2000-02-29 2000-02-29

Publications (2)

Publication Number Publication Date
PL362437A1 true PL362437A1 (pl) 2004-11-02
PL208368B1 PL208368B1 (pl) 2011-04-29

Family

ID=22683545

Family Applications (1)

Application Number Title Priority Date Filing Date
PL362437A PL208368B1 (pl) 2000-02-29 2001-02-26 Sposób diagnozowania jaskry

Country Status (12)

Country Link
US (3) US7033755B2 (pl)
EP (2) EP1974738A3 (pl)
JP (2) JP2004512008A (pl)
KR (1) KR100748297B1 (pl)
CN (3) CN101117644A (pl)
AU (2) AU4176801A (pl)
BR (1) BR0108802A (pl)
CA (2) CA2401775A1 (pl)
MX (1) MXPA02008487A (pl)
PL (1) PL208368B1 (pl)
WO (1) WO2001064949A2 (pl)
ZA (1) ZA200207647B (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7704498A (en) * 1997-05-29 1998-12-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Human frp and fragments thereof including methods for using them
US6600018B1 (en) * 2000-04-10 2003-07-29 The United States Of America As Represented By The Department Of Health And Human Services Secreted frizzled related protein, sFRP, fragments and methods of use thereof
US20030082233A1 (en) * 2000-12-01 2003-05-01 Lyons Karen M. Method and composition for modulating bone growth
TWI335221B (en) 2001-09-27 2011-01-01 Alcon Inc Inhibtors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma
US20050069893A1 (en) * 2002-03-01 2005-03-31 Josef Flammer Diagnostic method for glaucoma
EP1549144A4 (en) * 2002-10-04 2010-01-06 Univ California METHOD FOR THE TREATMENT OF CANCER BY INHIBITION OF THE WNT SIGNALING LINE
US20050037011A1 (en) * 2002-11-21 2005-02-17 Jones Stephen N. Diagnosing and treating hematopoietic cancers
WO2005111234A2 (en) * 2004-05-12 2005-11-24 Sugen, Inc. Methods of using zc1 and zc3 kinase substrate phosphorylation as biomarkers
CN1981054A (zh) * 2004-05-14 2007-06-13 加利福尼亚大学董事会 用抗wnt2单克隆抗体和sirna治疗癌症的方法
TWI401316B (zh) * 2004-12-23 2013-07-11 Alcon Inc 用於治療青光眼之血清澱粉樣蛋白Ａ的ＲＮＡｉ抑制作用
EP1844787A4 (en) * 2005-01-18 2011-10-19 Univ Kyoto DRUGS FOR NERVE CELL REGENERATION
US20060166251A1 (en) * 2005-01-26 2006-07-27 Archambault Joanne M Use of sFRPs as markers of BMP activity
EP1856259A1 (en) * 2005-03-11 2007-11-21 Alcon Inc. Rnai-mediated inhibition of frizzled related protein-1 for treatment of glaucoma
US20060239951A1 (en) * 2005-03-30 2006-10-26 Alexandre Valentin Methods for stimulating hair growth by administering BMPs
WO2006116503A2 (en) * 2005-04-26 2006-11-02 Irm Llc Methods and compositions for modulating wnt signaling pathway
NZ584848A (en) 2007-09-28 2012-09-28 Intrexon Corp Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
WO2019040311A1 (en) * 2017-08-20 2019-02-28 Regents Of The University Of California MODULATION OF WNT5A TO TREAT GLAUCOMA
CN114868204A (zh) * 2019-12-09 2022-08-05 赛诺菲 用于再利用药物的数据处理系统和方法
JP7692581B2 (ja) * 2020-06-09 2025-06-16 株式会社島津製作所 眼疾患に関する評価方法
CN113405645B (zh) * 2021-06-08 2022-09-27 哈尔滨工程大学 一种基于活塞的耐静水压光纤水听器

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5235043B2 (pl) * 1973-01-24 1977-09-07
GB8311018D0 (en) 1983-04-22 1983-05-25 Amersham Int Plc Detecting mutations in dna
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4833080A (en) 1985-12-12 1989-05-23 President And Fellows Of Harvard College Regulation of eucaryotic gene expression
US4998617A (en) 1986-09-15 1991-03-12 Laura Lupton Inc Facial cosmetic liquid make up kit
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5459039A (en) 1989-05-12 1995-10-17 Duke University Methods for mapping genetic mutations
FR2650840B1 (fr) 1989-08-11 1991-11-29 Bertin & Cie Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
US6004744A (en) 1991-03-05 1999-12-21 Molecular Tool, Inc. Method for determining nucleotide identity through extension of immobilized primer
WO1992015694A1 (en) 1991-03-08 1992-09-17 The Salk Institute For Biological Studies Flp-mediated gene modification in mammalian cells, and compositions and cells useful therefor
US5922773A (en) * 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
JPH08509857A (ja) 1993-01-07 1996-10-22 シーケノム・インコーポレーテッド マススペクトロメトリーによるｄｎａ配列決定法
US5593826A (en) 1993-03-22 1997-01-14 Perkin-Elmer Corporation, Applied Biosystems, Inc. Enzymatic ligation of 3'amino-substituted oligonucleotides
US5925748A (en) 1994-04-28 1999-07-20 The University Of Iowa Research Foundation DNA diagnostics for glaucoma
US5885776A (en) 1997-01-30 1999-03-23 University Of Iowa Research Foundation Glaucoma compositions and therapeutic and diagnositic uses therefor
US5916778A (en) 1994-04-28 1999-06-29 University Of Iowa Research Foundation Diagnostics based on a glaucoma causing gene
JP4063341B2 (ja) * 1994-07-06 2008-03-19 メイ株式会社 緑内障治療剤及び眼圧降下剤
US5789169A (en) 1994-11-03 1998-08-04 Regents Of The University Of California Methods for the diagnosis of glaucoma
US5798380A (en) 1996-02-21 1998-08-25 Wisconsin Alumni Research Foundation Cytoskeletal active agents for glaucoma therapy
EP1019043A4 (en) * 1996-05-07 2003-07-30 Univ Pennsylvania INHIBITORS OF GLYCOGEN SYNTHESIS KINASE 3 AND METHOD FOR THEIR IDENTIFICATION AND USE
US5928662A (en) 1996-07-31 1999-07-27 Phillips; Andrew F. Ocular drug delivery device
CA2274244C (en) * 1996-12-05 2008-11-04 Abbot F. Clark Methods for diagnosing glaucoma and discovering anti-glaucoma drugs
CN1253586A (zh) * 1997-03-24 2000-05-17 昂尼克斯药物公司 基于β－连环蛋白/转录因子相互作用诊断/治疗疾病的组合物和方法
WO1998044108A1 (en) * 1997-04-01 1998-10-08 The Regents Of The University Of California Diagnosis and prognosis of glaucoma
EP0879885A1 (en) * 1997-05-23 1998-11-25 Smithkline Beecham Corporation A novel human gene similar to a secreted murine protein sFRP-1
AU7704498A (en) * 1997-05-29 1998-12-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Human frp and fragments thereof including methods for using them
EP1012262A4 (en) 1997-08-12 2002-11-06 Human Genome Sciences Inc HFLP PROTEIN HFLP
DE19909251A1 (de) * 1998-02-21 1999-08-26 Max Delbrueck Centrum Mittel zur Therapie von menschlichen Erkrankungen, ausgehend von beta-Catenin, seine Herstellung und seine Verwendung
EP0943684A3 (en) * 1998-03-10 2002-01-23 Smithkline Beecham Plc Frizzled-like polypeptides and polynucleotides
JPH11292764A (ja) * 1998-04-07 1999-10-26 Mitsui Chem Inc グルタミン酸類が関与する疾患の治療および／または予防薬
US6378526B1 (en) * 1998-08-03 2002-04-30 Insite Vision, Incorporated Methods of ophthalmic administration
JP2003512304A (ja) 1999-09-13 2003-04-02 ワイス 医薬組成物および分泌フリズル化関連タンパクを用いる方法

Also Published As

Publication number Publication date
WO2001064949B1 (en) 2002-12-05
WO2001064949A9 (en) 2003-02-20
EP1974738A2 (en) 2008-10-01
CA2401775A1 (en) 2001-09-07
JP2012025763A (ja) 2012-02-09
AU4176801A (en) 2001-09-12
AU2001241768B2 (en) 2006-04-27
US7807355B2 (en) 2010-10-05
KR100748297B1 (ko) 2007-08-09
JP2004512008A (ja) 2004-04-22
WO2001064949A2 (en) 2001-09-07
CN100460874C (zh) 2009-02-11
EP1259648A2 (en) 2002-11-27
PL208368B1 (pl) 2011-04-29
KR20030005212A (ko) 2003-01-17
US7033755B2 (en) 2006-04-25
CA2729889A1 (en) 2001-09-07
ZA200207647B (en) 2003-12-23
US20060216732A1 (en) 2006-09-28
EP1974738A3 (en) 2008-12-17
CN1667416A (zh) 2005-09-14
CN1196797C (zh) 2005-04-13
US20090226425A1 (en) 2009-09-10
CN101117644A (zh) 2008-02-06
MXPA02008487A (es) 2002-12-13
WO2001064949A3 (en) 2002-09-19
BR0108802A (pt) 2003-12-23
US20020049177A1 (en) 2002-04-25
CN1426482A (zh) 2003-06-25

Similar Documents

Publication Publication Date Title
PL362437A1 (pl) Diagnostyka i leczenie jaskry
ATE502648T1 (de) Verfahren zur behandlung von autoimmunerkrankungen bei einem probanden und diagnostische in-vitro-assays
DE60207514D1 (de) Zusammensetzungen und Verfahren zum Nachweis und zur Behandlung von mit Chemokinrezeptoren verbundenen Krankheiten
WO2004113570A3 (en) Genotype test for dogs
WO2008005290A3 (en) Methods for testing anti-thrombotic agents
NZ334097A (en) Prolactin receptor gene as a genetic marker for increased litter size in pigs
WO2005001032A3 (en) Fine mapping of chromosome 17 quantitative trait loci and use of same for marker assisted selection
NO20074061L (no) DNA markorer for storfevekst
DE69728044D1 (de) Diagnostisches verfahren und gerät
Dürig et al. A novel MITF variant in a white American Standardbred foal.
WO2006101623A3 (en) Cstf1 and c20orf43 markers for meat quality and growth rate in animals
ATE463562T1 (de) Lp-pla2-aktivitätstest mit hohem durchsatz
DE60118913D1 (de) Transgenes tiermodell für neurodegenerative erkrankungen
AU2003216489A8 (en) Methods and compositions for pharmacological and toxicological evaluation of test agents
DE60200278D1 (de) Vorrichtung und Verfahren zur Beleuchtung des Melkstands
WO2003016495A3 (en) Transgenic rodents as animal models for modulation of b1 bradykinin receptor protein
ATE473009T1 (de) Hemmung der neurodegeneration
ATE357538T1 (de) Verfahren zur kit genotypierung von schweinen
Kazemi Mining the genome of livestock species to identify markers associated with economically relevant morphological traits and breed-specific features
WO2004071186A8 (en) Animal model for inflammatory bowel disease
DE602005024498D1 (de) Diagnostisches Verfahren zum Nachweis von der "Collie Eye Anomaly"
EP1003909A1 (en) Reproductive and genetic screening samples of mutagenised animals
DE50310939D1 (de) Verfahren zur bestimmung des allelischen zustandes am 5'-ende des alpha-s1-kaseingens
DE602004015622D1 (de) Verfahren zur diagnose von fettleibigkeit
Li et al. DNA markers for pig litter size

Legal Events

Date Code Title Description
RECP Rectifications of patent specification